

MATTIA ALBERTO
DI CIVITA
RESUME

PERSONAL INFORMATIONS

Name DI CIVITA MATTIA ALBERTO
Phone number +39 3200336473
E-mail m.dicivita@gmail.it ; mattia.alberto.dicivita@pec.it
Nationality Italy
Date and place of birth 08/05/1995 FORMIA (LT)

WORK EXPERIENCE

- Date March 2026 – Until now
- Name and address of employer Ospedale Sandro Pertini – Medical Oncology – Via dei Monti Tiburtini, 385/389 - 00157 Roma
- Type of business or sector Public Hospital / National Health System
- Occupation or position held Medical Oncologist
- Main activities and responsibilities Oncological Day Hospital Activities. Managing comprehensive inpatient and outpatient oncological care, prescribing systemic therapies, and participating in multidisciplinary tumor boards. Oncolo

- Date November 2025 – January 2026
- Name and address of employer Policlinico Umberto I – Medical Oncology – Viale Del Policlinico, 155, Rome
- Type of business or sector Public Hospital / National Health System
- Occupation or position held Oncologist Academic Trainee
- Main activities and responsibilities Day Hospital and emergency room activities; care for inpatients. Patients home care with supportive and analgesic therapies. Collaboration for clinical researches in the field of breast, lung, gastrointestinal and genitourinary cancer and supportive care. Supervisor: Prof. Daniele Santini

- Date February 2025 – October 2025
- Name and address of employer Istituto Nazionale Tumori- Oncologia Genitourinaria – via Giacomo Venezian, 1 Milan
- Type of business or sector Public Hospital / National Health System
- Occupation or position held Oncologist Academic Trainee
- Main activities and responsibilities Day Hospital and emergency room activities; care for inpatients. Patients home care with supportive and analgesic therapies. Collaboration for clinical researches in the field of genitourinary cancer. Supervisor: Dott. Giuseppe Procopio

- Date September 2021 – January 2025
- Name and address of employer Policlinico Umberto I – Medical Oncology A – viale del Policlinico, 155, Rome

- Type of business or sector *Public Hospital / National Health System*
- Occupation or position held *Oncologist Academic Trainee*
- Main activities and responsibilities *Day Hospital and emergency room activities; care for inpatients. Patients home care with supportive and analgesic therapies. Collaboration for clinical researches in the field of breast, lung, gastrointestinal and genitourinary cancer and supportive care. Supervisor: Prof. Daniele Santini*

- Date *January 2021 – September 2021*
- Name and address of employer *Regina Elena National Cancer Institut – Medical Oncology A – via Elio Chianesi, Rome*
- Type of business or sector *Public Hospital / National Health System*
- Occupation or position held *Oncologist Academic Trainee*
- Main activities and responsibilities *Day Hospital and emergency room activities; care for inpatients. Patients home care with supportive and analgesic therapies. Collaboration for clinical researches in the field of cancer patients during coronavirus pandemic, breast, lung cancer, sarcoma and supportive care. Collaboration in national and international phase II and III clinical studies. Supervisor: Prof. Francesco Cognetti*

- Date *August 2020 – January 2021*
- Name and address of employer *ASL ROMA 5 - Via Acquaregna, 1-15 Tivoli (RM)*
- Type of business or sector *Health Centre / National Health System*
- Occupation or position held *Independent Contractor Medical Doctor*
- Main activities and responsibilities *Patients home assistance.*

EDUCATION AND TRAINING

- Date *November 2023 - Ongoing*
- Name and type of organisation *First University of Rome “La Sapienza”. Division of Experimental Medicine*
- Type of qualification awarded *Ph.D. in “Network Oncology and precision Medicine” Coordinator prof.ssa Elisabetta Ferretti*

- Date *January 2021 – January 2026*
- Name and type of organisation *First University of Rome “La Sapienza”*
- Type of qualification awarded *Specialization in Medical Oncology. Graduation Grade: 70/70 with honours*

- Date *13th May 2021*
- Name and type of organization *First University of Rome “La Sapienza”*
- Type of qualification awarded *Basic Life Support (BLS) training course*

- Date *March 2020*
- Name and type of organisation *MIUR “Ministero dell’istruzione, dell’Università e della Ricerca”*
- Type of qualification awarded *Subscription to National Medical Register – Medical licence. N. 4369 Frosinone Province.*

- Date *2013 – 2019*
- Name and type of organisation *University of Rome “Tor Vergata”*
- Type of qualification awarded *Master’s degree in Medicine and Surgery. Graduation Grade: 110/110 with honours*

- Date *2008 – 2013*
- Name and type of organisation *Liceo Scientifico Statale “Gioacchino Pellicchia” – Loc. Folcara, Cassino FR*
- Type of qualification awarded *High School Leaving Certificate*

LANGUAGE

ITALIAN mother tongue

OTHER LANGUAGES *ENGLISH*
 • *Written* *Good Knowledge*
 • *Spoken* *Good Knowledge*

COMPUTER SKILLS *Advanced knowledge of Windows and Microsoft Office Pack.*

DRIVING LICENSE *B Category*

ATTACHMENT: PUBLICATIONS

Di Noia V, Renna D, Barberi V, Di Civita M, Riva F, Costantini G, Aquila ED, Russillo M, Bracco D, La Malfa AM, Giannarelli D, Cognetti F. The first report on coronavirus disease 2019 (COVID-19) vaccine refusal by patients with solid cancer in Italy: Early data from a single-institute survey.

Di Noia V, Riva F, Di Civita M, Cosimati A, Cognetti F. Reply to the letter entitled: Re: The first report on Covid-19 vaccine refusal by patients with cancer in Italy: Early data from a single-institute survey.

Roberto M, Arrivi G, Di Civita MA, Barchiesi G, Pilozi E, Marchetti P, Santini D, Mazzuca F, Tomao S. The role of CXCL12 axis in pancreatic cancer: New biomarkers and potential targets.

Carconi C, Cerreti M, Roberto M, Arrivi G, D'Ambrosio G, De Felice F, Di Civita MA, Iafrate F, Lucatelli P, Magliocca FM, Picchetto A, Picone V, Catalano C, Cortesi E, Tombolini V, Mazzuca F, Tomao S. The management of oligometastatic disease in colorectal cancer: Present strategies and future perspectives.

Marinelli D, FTGallina, MA Di Civita, A Torchia, R Giusti, A J Gelibter, M Roberto, M Verrico, M Occhipinti, A Botticelli, E Cortesi, F Facciolo, D Santini. Surgical and survival outcomes with perioperative or neoadjuvant immune-checkpoint inhibitors combined with platinum-based chemotherapy in resectable nscl: a systematic review and meta-analysis of randomised clinical trials.

Santamaria F, Roberto M, Buccilli D, Di Civita MA, Giancontieri P, Maltese G, Nicoletta F, Torchia A, Scagnoli S, Pisegna S, Barchiesi G, Speranza I, Botticelli A, Santini D. Clinical implications of the Drug-Drug Interaction in Cancer Patients treated with innovative oncological treatments.

Di Civita, M.A.; Torchia, A.; Santini, D.; Marinelli, D.; Magro, V.; Cerro, M.; Pappalardo, L.; Maltese, G.; Santamaria, F.; Zacco, L.; et al. Immunotherapy-Based Combinations in First-Line Urothelial Cancer: A Systematic Review and Individual Patient Data (IPD) Meta-Analysis. *Curr. Oncol.* 2024, 31, 4713-4727. <https://doi.org/10.3390/curroncol31080352>

Santini D, Li H, Roviello G, Park SH, Grande E, Kucharz J, Basso U, Fiala O, Monteiro FSM, Poprach A, Buti S, Molina-Cerrillo J, Catalano M, Buchler T, Seront E, Ansari J, Myint ZW, Ghosn M, Calabrò F, Kopp RM, Bhuvu D, Bourlon MT, Roberto M, Di Civita MA, Mollica V, Marchetti A, Soares A, Battelli N, Ricci M, Kanesvaran R, Bamias A, Porta C, Massari F, Santoni M. Real-World Primary Resistance to First-Line Immune-Based Combinations in Patients with Advanced Renal Cell Carcinoma (ARON-1). *Target Oncol.* 2024 Nov;19(6):893-903. doi: 10.1007/s11523-024-01096-3. Epub 2024 Sep 17. PMID: 39289313.

Salciccia S, Santarelli V, Di Pierro GB, Del Giudice F, Bevilacqua G, Di Lascio G, Gentilucci A, Corvino R, Brunelli V, Basile G, Scornajenghi CM, Santodirocco L, Gobbi L, Rosati D, Moriconi M, Panebianco V, Magliocca FM, Santini D, Di Civita MA, Forte F, Frisenda M, Franco G, Sciarra A. Real-Life Comparative Analysis of Robotic-Assisted Versus Laparoscopic Radical Prostatectomy in a Single Centre Experience. *Cancers (Basel)*. 2024 Oct 25;16(21):3604. doi: 10.3390/cancers16213604. PMID: 39518044; PMCID: PMC11545600.

Roberto M, Di Civita MA, Marinelli D, Torchia A, Cara N, Maltese G, Speranza I, Santini D. PARP inhibitor-based treatment in metastatic, castration-resistant prostate cancer (mCRPC): A systematic review and meta-analysis. *BJUI Compass*. 2025 Jan 14;6(1):e455. doi: 10.1002/bco2.455. PMID: 39877569; PMCID: PMC11771493.

Santamaria F, Roberto M, Maltese G, Nicoletta F, Torchia A, Buccilli D, Di Civita MA, Giancontieri P, Marinelli D, Cirillo A, Bianco V, Verrico M, Botticelli A, Santini D. Tyrosine-kinase inhibitors for lung or breast cancer and drug-drug interactions: a clinical guide. *Oncol Rev*. 2025 Sep 22;19:1612249. doi: 10.3389/or.2025.1612249. PMID: 41059172; PMCID: PMC12497703.

Torchia A, Sabatini A, Bengala E, Di Civita MA, Ciurluini F, Marinelli D, Giammaruco M, Laudisi A, Gelibter A, Minuti G, Landi L, Santini D, Cappuzzo F. First-line treatment in

EGFR-mutated non-small cell lung cancer: brief report of an individual patient data comparison of phase 3 clinical trials. *Lung Cancer*. 2025 Dec;210:108845. doi: 10.1016/j.lungcan.2025.108845. Epub 2025 Nov 19. PMID: 41270639.

Di Civita MA, Marinelli D, Michetti VM, Artemi A, Ballario A, Torchia A, Pappalardo L, Pecoraro M, Speranza I, Sciarra A, Panebianco V, Roberto M, Santini D. Immunotherapy combinations in favourable risk score metastatic renal cell carcinoma, an individual patients data metanalysis. *BMC Cancer*. 2026 Jan 8;26(1):206. doi: 10.1186/s12885-025-15462-5. PMID: 41507833; PMCID: PMC12888583.

**ADDITIONAL
INFORMATIONS:**

Since 2023 to 2025 I have been attending the below clinical trials according to G.C.P as Sub-Investigator:

-ASCENT-03: A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Do Not Express PD-L1 or in Patients Previously Treated With Anti-PD-(L)1 Agents in the Early Setting Whose Tumors Do Express PD-L1, GS-US-592-6238;

-ASCENT 04: A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced, Inoperable, or Metastatic Triple-Negative Breast Cancer, Whose Tumors Express PD-L1; GS-US-592-6173;

Coordinator, Meet Uro Young (Italian Research Group on genitourinary cancers) Meet Uro July 2025 – July 2027

In compliance with the Italian legislative Decree no. 196 dated 30/06/2003, I hereby authorize you to use and process my personal details contained in this document.

02/03/2026

